Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA-transfected dendritic cell vaccine (Oslo University Hospital)
- Development stage
- Unknown
- Lead developer
- Oslo University Hospital
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intranodal, Intradermal
01
Overview
This is an investigational autologous dendritic cell-based cancer vaccine developed by researchers at Oslo University Hospital (Norwegian Radium Hospital) for the treatment of metastatic androgen-resistant (castration-resistant) prostate cancer. The vaccine is produced by harvesting monocyte-derived dendritic cells from the patient and transfecting them with messenger RNA (mRNA) extracted from three allogeneic prostate cancer cell lines (DU-145, LNCaP, and PC-3) using electroporation. This approach allows the dendritic cells to present a broad spectrum of tumor-associated antigens to the patient's immune system. The vaccine is designed to elicit specific T-cell responses against prostate cancer cells. In Phase I/II clinical trials, the vaccine was administered either intranodally or intradermally and demonstrated a favorable safety profile, with approximately half of the patients developing specific immune responses and some showing decreases in prostate-specific antigen (PSA) levels.
- Other names
- Dendritic Cells (DC) prostatemRNA-transfected DC vaccine
Beyond the preview
Go deeper on mRNA-transfected dendritic cell vaccine (Oslo University Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA-transfected dendritic cell vaccine (Oslo University Hospital).